South Korean AI and Deep Tech Startups Target US Market Expansion

Nine early-stage South Korean startups recently competed at the DETO 2026 conference in Seoul, vying for a position in the 2027 Startup Battlefield 200 competition. The cohort represents a broad cross-section of the South Korean deep tech ecosystem, with companies specializing in healthcare AI, semiconductor efficiency, and autonomous mobility. Each of the participating firms has expressed a primary goal of expanding into the United States market.

Voinosis Leads with Healthcare AI

The competition winner, Voinosis, focuses on the intersection of artificial intelligence and neurology. Founded by Grace Shin, an otologic surgeon with over 25 years of experience, the startup has developed a tool that analyzes speech patterns—including pitch, pauses, and rhythm—to detect changes in brain health. In clinical trials with 146 participants, the company reported an 88% accuracy rate in screening for cognitive issues. Voinosis is currently seeking Series A funding to support its entry into US hospitals and senior living facilities.

Advancements in AI Hardware and Infrastructure

Among the other contenders, Ternell is addressing the high energy demands of AI processing. Founded by a former Samsung Electronics engineer, the startup is developing "T-SRAM," a new type of memory that utilizes a three-state system rather than the standard two. Tests on 28-nanometer chips indicated that this architecture could reduce data access energy by up to 71% while significantly increasing memory capacity per area.

The remaining startups showcased diverse applications for AI and automation:

• DeepFusion AI: A 4D radar imaging system for autonomous robots and defense.
• Riibotics: A middleware platform designed to deploy warehouse robotics within a single day.
• Awesome Lab: A heating system using water electrolysis intended for US HVAC integration.
• Crosshub: A cross-border identity verification and payment platform using zero-knowledge proofs.

What to watch next: Voinosis is expected to leverage its recent strategic investment from a South Korean pharmaceutical firm to accelerate its US market entry and clinical validation.